Dose escalation in patients receiving whole-brain radiotherapy for brain metastases from colorectal cancer
- PMID: 20127223
- DOI: 10.1007/s00066-010-2067-8
Dose escalation in patients receiving whole-brain radiotherapy for brain metastases from colorectal cancer
Abstract
Background and purpose: Whole-brain radiotherapy (WBRT) alone is the most common treatment for brain metastases from colorectal cancer, as most patients are not candidates for more aggressive therapies such as resection or radiosurgery. The standard WBRT regimen, 30 Gy in ten fractions (10 x 3 Gy), has generally resulted in poor outcomes. This study investigated whether an escalation of the WBRT dose improves these results.
Patients and methods: Data from 53 patients receiving WBRT alone for brain metastases from colorectal cancer were retrospectively analyzed. 10 x 3 Gy (n = 35) was compared to higher doses (40 Gy/20 fractions or 45 Gy/15 fractions; n = 18) for overall survival (OS) and local control (LC). Additional factors evaluated for prognostic importance included age, gender, performance status, number of metastases, and extracerebral metastases.
Results: The OS rates at 6 months were 17% after 10 x 3 Gy and 50% after 20 x 2 Gy/15 x 3 Gy (p = 0.014). On multivariate analysis, improved OS was significantly associated with higher WBRT dose (p = 0.047), Karnofsky Performance Score (KPS) > or = 70 (p = 0.034), less than four brain metastases (p = 0.036), and lack of extracerebral metastases (p = 0.010). The LC rates at 6 months were 17% after 10 x 3 Gy and 50% after higher doses (p = 0.018). On multivariate analysis of LC, higher WBRT dose was significant (p = 0.028). A trend was observed for KPS > or = 70 (p = 0.08) and less than four brain metastases (p = 0.06).
Conclusion: These data suggest that patients with brain metastases from colorectal cancer treated with WBRT alone appeared to benefit from escalation of the radiation dose beyond 10 x 3 Gy in terms of improved OS and LC.
Similar articles
-
Do patients receiving whole-brain radiotherapy for brain metastases from renal cell carcinoma benefit from escalation of the radiation dose?Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):398-403. doi: 10.1016/j.ijrobp.2009.08.022. Epub 2010 May 18. Int J Radiat Oncol Biol Phys. 2010. PMID: 20488627
-
Dose escalation of whole-brain radiotherapy for brain metastases from melanoma.Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):537-41. doi: 10.1016/j.ijrobp.2009.05.001. Epub 2009 Sep 3. Int J Radiat Oncol Biol Phys. 2010. PMID: 19733017
-
Hypofractionated whole-brain radiotherapy for multiple brain metastases from transitional cell carcinoma of the bladder.Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):404-8. doi: 10.1016/j.ijrobp.2009.07.1717. Epub 2010 Feb 18. Int J Radiat Oncol Biol Phys. 2010. PMID: 20171794
-
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Whole Brain Radiation Therapy in Adults With Newly Diagnosed Metastatic Brain Tumors.Neurosurgery. 2019 Mar 1;84(3):E159-E162. doi: 10.1093/neuros/nyy541. Neurosurgery. 2019. PMID: 30629211
-
Radiotherapy for metastatic brain tumors.Int J Clin Oncol. 2009 Aug;14(4):281-8. doi: 10.1007/s10147-009-0915-2. Epub 2009 Aug 25. Int J Clin Oncol. 2009. PMID: 19705237 Review.
Cited by
-
18F-FET-PET-based dose painting by numbers with protons.Strahlenther Onkol. 2010 Jun;186(6):320-6. doi: 10.1007/s00066-010-2014-8. Epub 2010 May 21. Strahlenther Onkol. 2010. PMID: 20559789
-
Survival and quality of life after whole brain radiotherapy with 3D conformal boost in the treatment of brain metastases.Med Pharm Rep. 2019 Jan;92(1):43-51. doi: 10.15386/cjmed-1040. Epub 2019 Jan 15. Med Pharm Rep. 2019. PMID: 30957086 Free PMC article.
-
Radiobiology and radiotherapy of brain metastases.Clin Exp Metastasis. 2017 Oct;34(6-7):411-419. doi: 10.1007/s10585-017-9865-7. Epub 2017 Nov 14. Clin Exp Metastasis. 2017. PMID: 29139010 Review.
-
Outcome after whole brain radiotherapy alone in intracranial leptomeningeal carcinomatosis from solid tumors.Strahlenther Onkol. 2012 Feb;188(2):148-53. doi: 10.1007/s00066-011-0025-8. Epub 2012 Jan 11. Strahlenther Onkol. 2012. PMID: 22231633
-
Hematogenous metastases in patients with Stage I or II endometrial carcinoma.Strahlenther Onkol. 2011 Dec;187(12):806-11. doi: 10.1007/s00066-011-2250-6. Epub 2011 Nov 17. Strahlenther Onkol. 2011. PMID: 22105770
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical